Abstract | BACKGROUND: MATERIALS AND METHODS: A total of 76 cases of various malignancies on EGFR inhibitors who developed cutaneous side effects while on therapy and reported or referred to us by oncologists from January 2017 to January 2018 were included in the study. All the patients who were on other associated medications or radiotherapy were excluded. RESULT: CONCLUSION: Although most of the skin toxicities associated with EGFR inhibitors can be managed conservatively, a critical analysis of the cases that are significantly affected due to these side effects is required in cohesion with the treating oncologist to improve the therapeutic compliance of the drug.
|
Authors | Neerja Saraswat, Aradhana Sood, Dharmesh Kumar, Rajesh Verma, Kumar Sushil |
Journal | Indian dermatology online journal
(Indian Dermatol Online J)
2019 May-Jun
Vol. 10
Issue 3
Pg. 251-255
ISSN: 2229-5178 [Print] India |
PMID | 31149566
(Publication Type: Journal Article)
|